We concluded that PCSK9 inhibitors are theguideline-recommended alternative therapy for SAMS, includingrhabdomyolysis-induced AKI. This evidence concerns the gene PCSK9 and short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.